Navigation Links
Akela Pharma reports results for third quarter of fiscal 2007
Date:11/9/2007

ation of the Fentanyl TAIFUN(R) Phase II trial program and the development of our product candidates.

The consolidated net loss for the third quarter of 2007 was $8.6 million, or ($0.73) per share and $23.8 million or ($2.03) per share year-to-date, compared with a consolidated net income for the former Pharma segment of $12.0 million and $0.8 million, respectively.

The Company had cash and cash equivalents as of September 30, 2007 of $15.1 million. compared with $35.3 million as of December 31, 2006.

THE ISSUER HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE SEC (FILE NO. 333-146684) FOR AN OFFERING OF ITS SECURITIES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER DOCUMENTS THE ISSUER HAS FILED WITH THE SEC FOR MORE COMPLETE INFORMATION ABOUT THE ISSUER AND THIS OFFERING. YOU MAY GET THESE DOCUMENTS FOR FREE BY VISITING EDGAR ON THE SEC WEB SITE AT http://WWW.SEC.GOV. ALTERNATIVELY, THE ISSUER, ANY UNDERWRITER OR ANY DEALER PARTICIPATING IN THE OFFERING WILL ARRANGE TO SEND YOU THE PROSPECTUS IF YOU REQUEST IT BY CONTACTING OPPENHEIMER AND CO. INC. AT 125 BROAD STREET, 16TH FLOOR, NEW YORK, NEW YORK 10004, ATTENTION: SYNDICATE DEPARTMENT, OR BY PHONE AT (212) 825 4341

About Akela Pharma Inc.

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

This news release contains certain forwar
'/>"/>

SOURCE Akela Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. Akela Pharma Inc. Completes Share Consolidation
3. AKELA Pharma Inc. announces U.S. public offering and proposed listing
4. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... of chronic inflammation in non-cancerous prostate tissue may have ... than those with no inflammation, according to results of ... Hopkins Kimmel Cancer Center. , The link between persistent ... so-called high-grade prostate cancer those with a Gleason ... of the most aggressive and rapidly growing prostate cancers. ...
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... 29, 2007 Traditionally, clinicians have relied on ... visits as the primary means of assessing patients ... could arise if important symptoms go unreported during ... A new study by researchers at Memorial Sloan-Kettering ...
... Nov. 29 Today, the Infectious,Diseases Institute (IDI) ... leader in HIV/AIDS prevention and treatment, as the ... joining IDI, Dr. Coutinho spent six years leading ... care and treatment,organization in Africa. His impressive accomplishments ...
... New MEDEX Global Group/Harvard Medical International Website goes beyond, ... the Lesser-Known Factors ... Healthcare, BALTIMORE, Nov. 29 Determining health risks ... incredibly complex.,According to the just published MEDEX 360m International ...
... Nov. 29 AtriCure, Inc.,(Nasdaq: ATRC ), a ... announced today that David J. Drachman, President and,Chief Executive ... Markets,2007 Healthcare Conference at the Millennium Broadway Hotel in ... ET., A live web cast and recording of ...
... 29 Specialty chemicals,maker Albemarle Corporation (NYSE: ... (also referred to as DBM, methylene dibromide, or,MDB) ... 2007, or as contracts allow., (Logo: ... needed to cover higher costs, in particular,higher raw ...
... on seizures linked to lamotrigine use, research shows , ... levels of the drug lamotrigine in pregnant women with epilepsy ... research shows. , Lamotrigine, an epilepsy drug, is taken by ... of causing birth defects. However, the drug has also been ...
Cached Medicine News:Health News:Cancer patients may benefit from reporting symptoms online in real time 2Health News:Cancer patients may benefit from reporting symptoms online in real time 3Health News:Cancer patients may benefit from reporting symptoms online in real time 4Health News:Infectious Diseases Institute Appoints Alex Coutinho, M.D as Executive Director 2Health News:Infectious Diseases Institute Appoints Alex Coutinho, M.D as Executive Director 3Health News:MEDEX 360m Rates the State of Global Medical Care for Travelers 2Health News:AtriCure to Present at BMO Capital Markets 2007 Healthcare Conference 2Health News:Albemarle to Raise Prices of Dibromomethane 2Health News:Tracking Drug Levels Helps Pregnant Women With Epilepsy 2
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Cardiovascular Patch utilizes advanced fluoropolymer ... around penetrating suture and decrease ... much as 88 percent. This ... retention, multi-directional strength and low ...
... surgery, modified Blalock-Taussig shunts provide palliation of ... GORE-TEX Vascular Grafts configured for Pediatric Shunts ... use as shunts in pediatric cardiac procedures. ... ease of implantation and take-down at total ...
... techniques for vascular surgery, and the accompanying ... specialized types of graft be developed. Grafts ... biocompatible, but also available in varying sizes ... Vascular Graft has long been the prosthetic ...
... have met the challenges of the most ... Recognized for exceptional performance and quality, they ... worldwide. These grafts require no preclotting, resist ... assure utmost thrombectomy safety. Gore vascular grafts ...
Medicine Products: